Latest Regulatory News

Patagonia Lithium has reached 200 metres depth at Cilon Well 8, reporting strong brine flow rates and specific gravity readings indicative of lithium presence, while confirming no environmental impact from drilling activities.

PEXA contested IPART’s regulatory approach to setting its Initial Asset Base during a public hearing, warning that the proposed valuation could jeopardise its financial sustainability and operational stability.

Control Bionics has closed its Share Purchase Plan, raising $256,500 and pushing total capital raised to $9.75 million, pending shareholder approval for the final tranche.

Orbminco has completed key drilling and metallurgical milestones at Majestic North, keeping its development timeline on track for a September Mining Development and Closure Proposal lodgement and final investment decision.

Solstice Minerals has delivered a standout quarter at its Nanadie Copper-Gold Project, extending mineralisation well beyond the current resource boundary with a massive 629m drill intercept. Backed by a strong $45 million cash position, the company is poised for further resource growth and exploration across its Eastern Goldfields assets.

Noumi Limited has struck a binding deal with major shareholder Arrovest to acquire all remaining shares via a scheme of arrangement, offering shareholders a 12.2% premium amid looming $610 million convertible note maturity.

Dundas Minerals has cleared a major regulatory hurdle with native title approval at its Capricorn Gold Project, enabling imminent drilling across its Kalgoorlie district portfolio.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

Larvotto Resources has kicked off staged commissioning at its Hillgrove Mine processing plant, marking a pivotal step toward becoming Australia’s top antimony producer with promising gold and tungsten prospects.

Havilah Resources has kicked off reverse circulation drilling at its Brooks Dam prospect near Kalkaroo, aiming to penetrate a stubborn gossan-chert horizon and better define underlying copper-gold mineralisation. The drilling is part of a strategic alliance with Sandfire Resources, which is also advancing its own large-scale drilling and prefeasibility work at Kalkaroo.

AFT Pharmaceuticals secures tentative FDA approval for Scomara cream to treat rare facial tumours but faces a US launch delay due to orphan drug exclusivity. The approval bolsters prospects in other markets where AFT expects competitive advantages.

Energy Transition Minerals (ASX:ETM) has completed its purchase of the Penouta Tin-Tantalum-Niobium mine in Spain, advancing its ambition to become a key European critical minerals producer with plans to restart operations.